SPOTLIGHT: Gilmartin testifies in Vioxx trial

Vioxx was important to Merck's financial future when the company launched the drug as other key patents were set to expire, according to testimony by the former CEO of the drug giant. But Raymond Gilmartin insisted that the company did not put profits ahead of safety in pushing the drug out into the marketplace. His videotaped deposition was played by Merck as part of its defense in a Texas trial. Story

Suggested Articles

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.